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ABSTRACT
Dibenzoylmethane (DBM), a β-diketone structural analogue of curcumin, has been reported to exhibit anti-tumorigenic and
chemopreventive activities in mouse mammary tumorigenesis. Our previous study indicated that DBM modulates estrogenic action
both in vitro and in vivo. In this report, the potential role of DBM as modulator of lipid metabolism in two mouse models was investigated. Several biomarkers and intermediate metabolites related to lipid consumption were measured. The results indicated that the
parametrial fat pad weight, the level of triglyceride in both CD-1 and Sencar mice fed with 1% DBM, was remarkably reduced. In
addition, the estradiol level, uterus and mammary gland weights were significantly decreased in CD-1 and young Sencar mice at
55 days of age (during the estrous phase of estrous cycle). The reduction of both estradiol level and triglyceride in serum would
explain the inhibitory effect of DBM on mammary tumorigenesis as a modulator in dietary lipid metabolism.
Key words: dibenzoylmethane, lipid metabolism, triglyceride, estradiol, mammary tumorigenesis

INTRODUCTION
Dibenzoylmethane (DBM), a β-diketone structural
analogue of curcumin, has been reported to exhibit antitumorigenic and chemopreventive activities(1-7). It modulates the Phase I/Phase II metabolic systems, induces
apoptosis in various cancer cells, and exerts beneficial
effects for the ischemic diseases as a metal-chelator (1,3,5,8).
Dibenzoylmethane has been recently reported to exhibit
chemopreventive activities in mammary tumorigenesis. Particularly, dietary DBM inhibits the incidence of
7,12-dimethylbenzanthracene (DMBA)-induced mouse
mammary tumorigenesis and decreases the number of
breast tumors per mouse as well as the formation of
DMBA-DNA adducts in mammary glands(2). In vitro
competitive estrogen receptor binding studies showed
direct binding between DBM and estrogen receptor in
vitro(9). Further in vivo proliferation studies implicated
the potential role of DBM as an anti-estrogenic agent(2).
In molecular level, we demonstrated that DBM strongly
* Author for correspondence. Tel: +886-2-2782-1862;
Fax: +886-2-2786-4291; E-mail: cclin@cc.cust.edu.tw.

inhibited the E2-induced proliferation in both the human
breast cancer cell line MCF-7 and the mouse model,
reduced the expression of bcl-2, c-myc, Ha-ras and,
hTERT and acted as an anti-estrogenic agent by attenuating the ER-ERE binding within the regulatory regions of
these oncogenes(10).
Dietary lipid has been the major focus in the search
for dietary causes of breast cancer. In 1970, a report
indicated that the occurrence of breast cancer in U.S.
whites was six times higher than that in Asians (11). This
large variation in risk was not due to the genetic differences, but dietary factors. However, a relatively higher
rate of breast cancer incidence among Japanese who have
migrated to the United States was observed(12). Epidemiological studies indicated that Asian women at low risk for
breast cancer have been consistently shown to have lower
urinary and blood levels of estrogens than Caucasian
women at high risk(13). Strong support for a role of postmenopausal estrogens and risk of breast cancer indicated
that post-menopausal women who subsequently developed breast cancer showed a 15% higher mean concentration of serum estradiol than women who did not (14). In
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1999, a meta-analysis of dietary fat intervention studies
by Wu et. al. indicated that reducing fat consumption to
below 20% of calories would reduce the risk of breast
cancer and dietary lipid reduction could result in lower
serum estradiol levels(15). This is a substantial evidence
to support the potential of breast cancer prevention
through dietary factors, especially lipid consumption. In
spite of that, the relationship between estradiol level and
lipid consumption has not been elucidated, but is crucial
to explain the way dietary lipid modulates mammary
carcinogenesis.
Our previous study indicated that DBM would
modulate the estrogenic action as well as serum estradiol
level found in vivo, and the potential role of DBM as a
modulator of lipid metabolism was investigated. These
results would provide some clues to explain the relationship among lipid, estrogen, and mammary tumorigenesis
through understanding the mechanisms of DBM on lipid
metabolism in animal models. In our studies, several
biomarkers and intermediate metabolites related to lipid
consumption were measured. These included parametrial
fat pad weight, progesterone, cholesterol, triglyceride and
fatty acid profile in serum. In addition, weekly food and
water consumptions were recorded and compared. The
information should provide substantial evidence to evaluate the potential role of DBM as a modulator in dietary
lipid metabolism as well as its relation with estrogendependent mammary carcinogenesis.

MATERIALS AND METHODS
I. Animals and Treatment
Dibenzoylmethane (DBM) was purchased from
Aldrich (Milwaukee, WI, U.S.A.). AIN-76A diet and 1%
DBM in AIN-76A diet were purchased from Research
Diets, Inc. (New Brunswick, NJ, U.S.A.). Female CD-1
mice (23 days old) or female Sencar mice purchased from
Charles River Breeding Laboratories (Kingston, NY,
U.S.A.) were given the AIN76A diet or 1% DBM in the
AIN76A diet for several weeks. All experiments were
conducted in the animal facility at Rutgers University
(Busch Campus, Piscataway, NJ, U.S.A.) according to
the NIH guideline. The mice were housed (ten mice per
cage) in a room with controlled temperature (72 ± 2°F)
and humidity (40 ± 10%). All experiments were done
according to the animal protocol approved by the Rutgers
University Animal Care and Use Committee. During
the period of experiment, weekly water, food consumption, and body weight of mice were recorded. At the end
of experiment, all mice were fasted overnight, sacrificed
and parametrial fat pad weights were measured. Determination of estrous cycle was followed by the procedures recorded in reference (2). The blood samples were
collected and the serum was prepared by centrifugation
of the collected blood and stored at -80°C. Concentrations

of progesterone, cholesterol, triglyceride, HDL and estradiol were assayed by commercially available kits from
Sigma Chemical Co. (St. Louis, MO, U.S.A.) and Oxford
Biomedical Research Inc. (Oxford, MI, U.S.A.). Fatty acid
profiles were determined by gas chromatography.
II. Measurement of Hormone Levels in Serum
Determination of the serum estradiol and progesterone concentrations was done by enzyme-linked immunosorbent assay (ELISA). The serum was extracted with
ethyl ether (or petroleum ether for progesterone assay)
and the concentrated residue was dissolved in extraction buffer provided by a commercial kit. The samples
and enzyme conjugate (estradiol-horse radish peroxidase) were added to a microplate with the corresponding
antibody pre-coated on each well and the mixture was
incubated at room temperature for 1 h. During this time,
competition for the limited binding sites should take
place. After washing for 3 times with wash buffer to
remove unbound material, the quantity of bound enzyme
conjugate was determined by adding the substrate (3,3’,
5,5’-tetramethylbenzidine and hydrogen peroxide). An
optimal color was developed after incubation for 30 min
and the absorbance reading of each well at 650 nm
was measured by a microplate reader. The calculation
of hormone concentration in samples was performed
according to the manual, using a standard curve.
III. Measurement of Lipid Metabolites in Serum
The Sigma diagnostics triglyceride reagent was used
for the measurement of the triglyceride levels. Briefly,
the triglycerides in the sample were hydrolyzed to glycerol and fatty acids with lipoprotein lipase (Reagent B).
After a series of coupled enzymatic reactions catalyzed
by glycerol kinase, glycerol phosphate oxidase and
peroxidase as well as appropriate substrates (Reagent A),
a quinone imine was produced. The absorbance of both
standard and samples at 540 nm was measured and the
total glycerol content was calculated. For the determination of true triglycerides, the concentration of endogenous glycerol, measured by using reagent containing no
lipase (Reagent A), was subtracted from the total glycerol
content determined previously.
To measure the quantity of cholesterol in serum,
a commercial diagnostic reagent containing esterase,
enzymes and substrates for colorimetric determination was
added to the samples. After 10 min of incubation at room
temperature, the absorbance reading of both standard and
samples at 500 nm was determined and the concentration
of cholesterol in serum sample was calculated.
For the determination of high density lipoprotein
(HDL) level in serum, a precipitation procedure was
used to separate the HDL from low density lipoprotein
(LDL). Firstly, a reagent containing phosphotungstic acid
and magnesium chloride (PTA/MgCl 2) was added to the
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sample to precipitate LDL fraction in the serum. After
centrifugation at 3000 rpm, the supernatant containing
HDL was subjected to the regular method for cholesterol determination as described previously. The level
of LDL cholesterol could be calculated from the known
concentrations of total cholesterol, HDL cholesterol and
triglycerides by using an equation (LDL = Total cholesterol – HDL cholesterol – Triglycerides/5), provided that
triglycerides are less than 400 mg/dL.
IV. Determination of Fatty Acid Profile in Serum
To gain insight into the effect of DBM on fatty acid
compositions, the ratio of saturated to unsaturated fatty
acids, and ω3/ω6 PUFA, the profile of fatty acids were
was determined by gas chromatography. Fatty acids were
extracted from serum with hexane and derivatized with
14% trifluoroborane in methanol. The methyl esters of
fatty acids were analyzed by a Siemens Sichromat gas
chromatograph fitted with an automatic injection system
and a hydrogen flame ionization detector. A SP-2330
capillary column (30 m × 0.25 mm × 0.2 µm film thickness) from Supelco was used. The oven temperature was
programmed from 70°C to 180°C at a rate of 25°C/min
and held at 180°C for 30 min and then increased to 220°C
for 3 min. The flow rate of the helium carrier gas was
1.2 mL/min. The injection port and detector temperatures were 250°C and 260°C, respectively. The autosampler was programmed to rinse the 10 µL syringe, once
with sample, pumped three times to remove air bubbles,
and then inject 5 µL of sample with a split ratio of about
10 : 1. The syringe was then rinsed five times with
solvent. A Perkin-Elmer model LCI-100 integrator was
used for the integration of peak areas and the concentration of each fatty acid methyl ester was calculated using
standard curves from each reference.

RESULTS AND DISCUSSION
I. Biological Effects of Dietary DBM in the Treatment of
CD-1 and Sencar Mice
The weekly body weight, food and water consumption of both CD-1 and Sencar mice were recorded and
summarized in Table 1 and Table 2, respectively. CD-1
and Sencar mice were used in our previous study on
the inhibitory effects of DBM on skin and mammary
carcinogenesis. In the case of CD-1 mice, the body
weight showed no change between the control diet

Table 1. Effect of oral administration of 1% DBM diet on body
weight, food and water consumption in CD-1 mice
Group

Week 1

Week 3

Week 4

Body weight (g/mouse)
Control AIN 76A diet

12.2 ± 0.2

21.3 ± 0.3

23.0 ± 0.3

1% DBM in control diet

12.8 ± 0.2

19.4 ± 0.4

23.0 ± 0.4

Food consumption (g/mouse/day)
Control AIN 76A diet

3.3 ± 0.1

3.1 ± 0.1

1% DBM in control diet

4.2 ± 0.2*

3.8 ± 0.1*

Water consumption (mL/mouse/day)
Control AIN 76A diet

4.6 ± 0.3

4.8 ± 0.3

1% DBM in control diet

7.3 ± 0.4*

9.1 ± 0.6*

Female CD-1 mice were fed AIN 76A diet or 1% DBM in the
AIN 76A diet starting at 23 days of age and ending at 55 days of
age. Body weight, food consumption and water consumption were
recorded weekly. Data are expressed as the mean ± S.E.
* S tatistically different from the control AIN 76A diet group
( p < 0.05) as determined by Student’s t-test.

Table 2. Effect of oral administration of 1% DBM diet on body weight, food and water consumption in Sencar mice
Group

Week 1

Week 2

Week 3

Week 4

Week 5

Week 6

Body weight (g/mouse)
Control AIN 76A diet

28.2 ± 0.4

28.0 ± 0.4

30.4 ± 0.5

31.6 ± 0.5

31.9 ± 0.6

32.9 ± 0.6

1% DBM in control diet

28.1 ± 0.5

29.3 ± 0.5

31.2 ± 0.5

32.5 ± 0.5

32.7 ± 0.6

33.3 ± 0.6

Food consumption (g/mouse/day)
Control AIN 76A diet

3.6 ± 0.1

3.7 ± 0.1

3.7 ± 0.1

3.6 ± 0.2

3.9 ± 0.2

1% DBM in control diet

3.8 ± 0.1

4.2 ± 0.2

4.4 ± 0.1*

4.0 ± 0.0

4.3 ± 0.2

Water consumption (mL/mouse/day)
Control AIN 76A diet

6.4 ± 0.3

5.9 ± 0.2

6.3 ± 0.4

6.2 ± 0.4

5.0 ± 0.5

1% DBM in control diet

9.6 ± 0.8*

9.2 ± 1.2*

10.6 ± 0.8*

9.6 ± 0.7*

12.3 ± 1.3*

Female Sencar mice were fed AIN 76A diet or 1% DBM in AIN 76A diet starting at 26 days of age and ending after 5 weeks. Body weight,
food consumption and water consumption were recorded weekly. Data are expressed as the mean ± S.E.
* Statistically different from the control AIN 76A diet group (p < 0.05) as determined by Student’s t-test.
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and the 1% DBM group after four weeks of administration. Interestingly, the CD-1 mice that were fed
with 1% DBM diet consumed more food (average
of 4.0 ± 0.2 compared with 3.2 ± 0.1 g/mouse/day
for control diet mice) and water (average of 8.2 ± 0.5
compared with 4.7 ± 0.3 mL/mouse/day for control diet
mice) during week 3 and week 4. The 1% DBM group
showed significant reduction ( p < 0.05) in parametrial
fat pad weight, uterus weight, while the liver weight was
significantly increased ( p < 0.05) at the end of the experiment (Table 3).
In the case of Sencar mice, the body weight
showed no change between the control diet and 1%
DBM diet groups after five weeks of administration.
Similarly with the CD-1 mice, the mice fed with 1%
DBM diet consumed more food (average of 4.1 ± 0.1
compared with 3.7 ± 0.1 g/mouse/day for control diet
mice) and water (average of 10.3 ± 1.0 compared with
6.0 ± 0.4 mL/mouse/day for control diet mice). In addition,
the 1% DBM diet group showed significant reduction
(p < 0.05) in parametrial fat pad weight, mammary gland
weight, but not in uterus weight (p = 0.636) while the liver
weight significantly increased (p < 0.05) at the end of the
experiment (Table 4). The unchanged body weight during
the short-term treatment in both strains of mice suggested
low toxicity for DBM.

Table 3. Biological effects of dietary DBM and measurements of
serum concentrations of hormones and lipids in CD-1 mice
Biological effects or
substances assayed

Control diet
(n = 20)

1% DBM diet
(n = 20)

Body weight (g)

23.0 ± 0.3

23.0 ± 0.4

Abdominal fat weight (g)

0.35 ± 0.04

0.26 ± 0.02*

Uterus weight (g)

0.28 ± 0.02

0.21 ± 0.01*

Liver weight (g)

1.26 ± 0.04

2.11 ± 0.01*

Estradiol (pg/mL)

77.8 ± 11.6

46.4 ± 5.4*

Cholesterol (mg/dL)

93.6 ± 7.0

244.0 ± 14.6*

HDL (mg/dL)

74.6 ± 0.2

150.6 ± 8.9*

Total glycerol (mg/dL)

82.1 ± 2.5

41.3 ± 3.5*

Triglyceride (mg/dL)

59.3 ± 3.4

24.2 ± 5.5*

Progesterone (ng/mL)

12.3 ± 1.3

13.4 ± 2.3

Female CD-1 mice were fed AIN 76A diet or 1% DBM in AIN 76A
diet starting at 23 days of age and ending at 55 days of age. The
mice were killed and the body, abdominal, uterus and liver weights
were determined. Concentrations of serum hormones and lipids
were measured by commercially available kits. Data are expressed
as the mean ± S.E.
* S tatistically different from the control AIN 76A diet group
(p < 0.05) as determined by Student’s t-test.

II. Serum Concentration of Hormones and Lipids in CD-1
and Sencar Mice
The hormone and lipid levels in serum of both CD-1
and Sencar mice were examined and compared. As
shown in Table 3, the concentration of estradiol in 1%
DBM group (46.4 ± 5.4 pg/mL) was significantly reduced
to 40% that of the control diet group (77.8 ± 11.6 pg/mL)
in CD-1 mice. However, no significant difference in the
progesterone level ( p = 0.688) was observed. The effect
of DBM on lipid metabolism was examined by measuring
the concentrations of triglyceride, cholesterol and HDL.
1% DBM group showed marked reduction (approximately
50%) in both triglyceride total glycerol levels, compared
with the control diet group. Inversely, the concentrations of cholesterol and HDL in 1% DBM group were
more than two folds higher than those in the control
group. These significant fat biomarker changes implied
an important role of DBM on the modulation of lipid
metabolism.
In the case of Sencar mice, the concentration of
estradiol in the 1% DBM group (77.8 ± 7.0 pg/mL)
was not significantly different ( p = 0.433) from that
of the control diet group (85.4 ± 6.1 pg/mL) (Table 4).
Inversely, significant difference was observed in the
progesterone level ( p < 0.005). The effect of DBM
on lipid metabolism was examined by measuring the
concentrations of triglyceride, cholesterol and HDL.
Similar to the case of CD-1 mice, the 1% DBM group
showed marked reduction (approximately 50%) in both

Table 4. Biological effects of dietary DBM and measurements of
serum concentrations of hormones and lipids in Sencar mice
Biological effects or
substances assayed

Control diet
(n = 26)

1% DBM diet
(n = 25)

Body weight (g)

32.9 ± 0.6

33.3 ± 0.6

Abdominal fat weight (g)

0.97 ± 0.07

0.76 ± 0.07*

Uterus weight (g)

0.16 ± 0.01

0.17 ± 0.02

Mammary gland weight (g)

0.15 ± 0.01

0.12 ± 0.01*

Liver weight (g)

1.91 ± 0.07

2.94 ± 0.04*

Estradiol (pg/mL)

85.4 ± 6.1

77.8 ± 7.0

107.0 ± 13.7

231.9 ± 7.5*

HDL (mg/dL)

72.4 ± 9.5

112.6 ± 7.3*

Total glycerol (mg/dL)

92.1 ± 13.1

58.3 ± 3.3

Triglyceride (mg/dL)

60.0 ± 11.6

24.2 ± 6.3*

Progesterone (ng/mL)

9.41 ± 0.92

4.36 ± 0.29*

Cholesterol (mg/dL)

Female Sencar mice were fed AIN 76A diet or 1% DBM in AIN 76A
diet starting at 26 days of age and ending after 5 weeks. The mice
were killed and the body, abdominal, uterus and liver weights were
determined. Concentrations of serum hormones and lipids were
measured by commercially available kits. Data are expressed as the
mean ± S.E.
* S tatistically different from the control AIN 76A diet group
(p < 0.05) as determined by Student’s t-test.
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Table 5. Biological effects of dietary DBM and measurements of
serum concentrations of hormones and lipids in immature Sencar
mice
Biological effects or
substances assayed

Control diet
(n = 15)

1% DBM diet
(n = 17)

Body weight (g)

29.0 ± 1.0

28.0 ± 0.9

Abdominal fat weight (g)

0.58 ± 0.06

0.41 ± 0.05*

Uterus weight (g)

0.20 ± 0.14

0.15 ± 0.02

Mammary gland weight (g)

0.09 ± 0.01

0.07 ± 0.01*

Liver weight (g)

1.64 ± 0.06

2.51 ± 0.09*

Estradiol (pg/mL)

558.1 ± 100.0

221.7 ± 9.6*

Cholesterol (mg/dL)

111.3 ± 4.0

271.1 ± 12.6*

73.0 ± 0.4

133.9 ± 2.4*

Total glycerol (mg/dL)

161.7 ± 3.4

66.2 ± 3.7*

Triglyceride (mg/dL)

119.5 ± 3.4

39.5 ± 3.6*

HDL (mg/dL)

Progesterone (ng/mL)

5.84 ± 1.66

5.75 ± 0.88

Female Sencar mice were fed AIN 76A diet or 1% DBM in AIN
76A diet starting at 21 days of age until 50 days of age. The mice
were killed and the body, abdominal, uterus and liver weights were
determined. Concentrations of serum hormones and lipids were
measured by commercially available kits. Data are expressed as the
mean ± S.E.
* S tatistically different from the control AIN 76A diet group
(p < 0.05) as determined by Student’s t-test.

triglyceride total glycerol levels, compared with the
control diet group. The concentrations of cholesterol
and HDL in the 1% DBM group were more than two
folds higher than those in the control group. In another
set of experiment shown in Table 5, immature Sencar
mice were fed either control or 1% DBM diet until 50
days of age, when the biological effects and biomarker
changes were the same as observed in the matured
Sencar mice as described previously, except the concentration of estradiol showed significant difference
between the control diet group (558.1 ± 100.0 pg/mL)
and 1% DBM group (221.7 ± 9.6 pg/mL).
From the breast cancer research, it has been found
that dietary lipid reduction can lower serum estradiol
level, which in turn, results in reducing the mitogenic
effect of estradiol toward tumor promotion(15,16). For the
mechanisms involved, dietary lipid has been shown to
modulate carcinogenic process through the regulation of
prostaglandin biosynthesis (17). The possible mechanisms
include PGE2-induced expression of estrogen biosynthesis, the inter-relation of metabolic pathways between
lipid and estradiol. However, they all need to be further
investigated and confirmed.
In this study, the remarkable reduction on parametrial fat pad weight and the level of triglyceride in both
CD-1 and Sencar mice explained the potential role of

Table 6. Effect of dietary DBM on the fatty acid profile in serum in
CD-1 mice
Concentration (µg/mL)

Fatty acid

Control diet

DBM diet

Palmitic acid (C16 : 0)

129 ± 25

132 ± 69

Stearic acid (C18 : 0)

203 ± 25

221 ± 59

27 ± 3

30 ± 13

Oleic acid (C18 : 1)
Linoleic acid (C18 : 2)

6 ± 0.2

3 ± 0.6*

Linolenic acid (C18 : 3)

4 ± 0.8

6±2

Arachidonic acid (C20 : 4)

6 ± 0.4

7±1

Eicosapentaenoic acid (C20 : 5)

9±1

12 ± 0.1

332 ± 50

353 ± 128

Total unsaturated fatty acids (U)

52 ± 5

58 ± 17

Total polyunsaturated fatty acids
(PU)c

25 ± 2

28 ± 4

S/U

6.6

6.1

S/PU

13.3

12.6

Total saturated fatty acids (S)a
b

Female CD-1 mice were fed AIN 76A diet or 1% DBM in AIN 76A
diet starting at 23 days of age and ending at 55 days of age. The mice
were killed and the serum was extracted with hexane. The fatty acids
were derivatized with 14% trifluoroborane in methanol and analyzed
by gas chromatography. The concentration of each fatty acid methyl
ester was calculated using standard curves from each reference. Data
are expressed as the mean ± S.E. from three determinations.
a
C16 : 0, C18 : 0
b
C18 : 1, C18 : 2, C18 : 3, C20 : 4, C20 : 5
c
C18 : 2, C18 : 3, C20 : 4, C20 : 5
* S tatistically different from the control AIN 76A diet group
(p < 0.05) as determined by Student’s t-test.

DBM as a modulator of lipid metabolism. In addition,
the decrease in estradiol level, uterus and mammary
gland weights in CD-1 and Sencar mice at 55 days of
age (during the estrous phase of estrous cycle) indicated that DBM would either interfere with the generation of estrogen through the lipid metabolic pathway in
fat tissue or influence the metabolism of estradiol by the
induction of enzymes, as implicated in the increased
liver weight. The high cholesterol and HDL levels would
lead to further investigation on the effect of DBM on the
pathway involved in the generation of cholesterol, especially the reductase HMG-CoA, a rate-limiting enzyme
in this process.
III. Fatty Acid Profile in Serum
In order to investigate the effect of DBM on fatty
acid compositions in serum, the fatty acid profiles of
both the control and 1% DBM groups in CD-1 and Sencar
mice were examined and compared (Tables 6 and 7). For
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Table 7. Effect of dietary DBM on the fatty acid profile in serum in
Sencar mice
Concentration (µg/mL)

Fatty acid

Palmitic acid (C16 : 0)
Stearic acid (C18 : 0)
Oleic acid (C18 : 1)

Control diet

DBM diet

86 ± 14

53 ± 13

149 ± 6

139 ± 16

23 ± 1

9 ± 1*

Linoleic acid (C18 : 2)

5 ± 0.1

3±1

Linolenic acid (C18 : 3)

3 ± 0.1

3 ± 0.5

Arachidonic acid (C20 : 4)

6 ± 0.3

8±1

8±2

8 ± 0.0

Eicosapentaenoic acid (C20 : 5)
Total saturated fatty acids (S)

a

235 ± 20

192 ± 29

Total unsaturated fatty acids (U)b

45 ± 4

31 ± 4

Total polyunsaturated fatty acids
(PU)c

22 ± 3

22 ± 3

S/U

5.2

6.2

S/PU

10.7

8.7

Female Sencar mice were fed AIN 76A diet or 1% DBM in AIN 76A
diet starting at 26 days of age and ending after 5 weeks. The mice
were killed and the serum was extracted with hexane. The fatty
acids were derivatized with 14% trifluoroborane in methanol and
analyzed by gas chromatography. The concentration of each fatty
acid methyl ester was calculated using standard curves from each
reference. Data are expressed as the mean ± S.E from three determinations.
a
C16 : 0, C18 : 0
b
C18 : 1, C18 : 2, C18 : 3, C20 : 4, C20 : 5
c
C18 : 2, C18 : 3, C20 : 4, C20 : 5
* S tatistically different from the control AIN 76A diet group
(p < 0.05) as determined by Student’s t-test.

saturated, unsaturated and polyunsaturated fatty acids,
no significant change was observed between the two
groups in both mouse strains. The ratios of total saturated fatty acids to total unsaturated fatty acids (S/U),
and total saturated fatty acid to total polyunsaturated
fatty acids (S/PU) were not significantly different.
Both epidemiological data and experimental animal
studies have indicated the relationship between dietary
lipid intake as well as the type of lipid consumed with
the incidence of cancers (18-20). Several studies indicated
that diets high in ω-6 polyunsaturated fatty acids (PUFA)
are associated with increased breast cancer risk. On the
contrary, consumption of oleic acid, a monounsaturated
fatty acid found in olive oil, and ω-3 PUFAs, which are
present in certain fish and fish oils, may reduce risk of
breast cancer. In experimental animal carcinogenic and
in vitro models, the development of tumors has been
found to be enhanced by ω-6 PUFA, but inhibited by
ω-3 PUFA(21,22). Studies indicated that most eicosanoids,

O

OH

H3CO

HO

OCH3

Curcumin

O

OH

OH

Dibenzoylmethane

Figure 1. Structures of curcumin and dibenzoylmethane

metabolites of arachidonic acid (ω-6 PUFA), are biologically active and act as inflammatory inducers involved
in the process of tumor promotion(23). Nevertheless, our
results ruled out the possibility that DBM inhibits the
formation of mammary tumor by modulating the type of
fatty acid formed in serum.
In summary, our previous study indicated that
DBM would modulate the estrogenic action both in vitro
and in vivo. In this report, the results indicated that the
mice that were fed dietary DBM showed reduced parametrial fat pad weight and lower level of triglyceride. In
addition, the estradiol level, uterus and mammary gland
weights were significantly decreased in CD-1 and young
Sencar mice at 55 days of age (during the estrous phase
of estrous cycle), indicating that DBM would either interfere with the generation of estrogen through the lipid
metabolic pathway or influence the metabolism of estradiol by the induction of enzymes, as implicated in the
increased liver weight. The reduction of both estradiol
level and triglyceride in serum would explain the inhibitory effect of DBM on mammary tumorigenesis in part
from its role as a modulator in dietary lipid metabolism.

REFERENCES
1. Jackson, K. M., DeLeon, M., Verret, C. R. and Harris,
W. B. 2002. Dibenzoylmethane induces cell cycle
deregulation in human prostate cancer cells. Cancer
Lett. 178: 161-165.
2. Lin, C. C., Lu, Y. P., Lou, Y. R., Ho, C. T., Newmark,
H. H., MacDonald, C., Singletary, K. W. and Huang,
M. T. 2001. Inhibition by dietary dibenzoylmethane of
mammary gland proliferation, formation of DMBADNA adducts in mammary glands, and mammary
tumorigenesis in Sencar mice. Cancer Lett. 168:
125-132.
3. MacDonald, C. J., Ciolino, H. P. and Yeh, G. C. 2001.
Dibenzoylmethane modulates aryl hydrocarbon
receptor function and expression of cytochromes P50

345
Journal of Food and Drug Analysis, Vol. 18, No. 5, 2010

1A1, 1A2, and 1B1. Cancer Res. 61: 3919-3924.
4. Singletary, K. and MacDonald, C. 2000. Inhibition of
benzo[a]pyrene- and 1,6-dinitropyrene-DNA adduct
formation in human mammary epithelial cells bydibenzoylmethane and sulforaphane. Cancer Lett. 155: 47-54.
5. Dinkova-Kostova, A. T. and Talalay, P. 1999. Relation
of structure of curcumin analogs to their potencies as
inducers of Phase 2 detoxification enzymes. Carcinogenesis 20: 911-914.
6. Huang, M. T., Lou, Y. R., Xie, J. G., Ma, W., Lu, Y. P.,
Yen, P., Zhu, B. T., Newmark, H. and Ho, C. T. 1998.
Effect of dietary curcumin and dibenzoylmethane on
formation of 7,12-dimethylbenz[a]anthracene-induced
mammary tumors and lymphomas/leukemias in Sencar
mice. Carcinogenesis 19: 1697-1700.
7. Singletary, K., MacDonald, C., Iovinelli, M., Fisher,
C. and Wallig, M. 1998. Effect of the beta-diketones
diferuloylmethane (curcumin) and dibenzoylmethane
on rat mammary DNA adducts and tumors induced
by 7,12-dimethylbenz[a]anthracene. Carcinogenesis 19:
1039-1043.
8. Mabjeesh, N. J., Willard, M. T., Harris, W. B., Sun, H.
Y., Wang, R., Zhong, H., Umbreit, J. N. and Simons,
J. W. 2003. Dibenzoylmethane, a natural dietary
compound, induces HIF-1 alpha and increases expression of VEGF. Biochem. Biophys. Res. Commun. 303:
279-286.
9. Lin, C. C., Ho, C. T. and Huang, M. T. 2001. Mechanistic studies on the inhibitory action of dietary dibenzoylmethane, a beta-diketone analogue of curcumin,
on 7,12-dimethylbenz[a]anthracene-induced mammary
tumorigenesis. Proc. Natl. Sci. Counc. Repub. China B.
25: 158-165.
10. Lin, C. C., Tsai, Y. L., Huang, M. T., Lu, Y. P., Ho, C.
T., Tseng, S. F., and Teng, S. C. 2006. Inhibition of
estradiol-induced mammary proliferation by dibenzoylmethane through the E2-ER-ERE-dependent
pathway. Carcinogenesis 27: 131-136.
11. MacMahon, B., Cole, P. and Brown, J. 1973. Etiology
of human breast cancer: a review. J. Natl. Cancer Inst.
50: 21-42.
12. Wakai, K., Suzuki, S., Ohno, Y., Kawamura, T., Tamakoshi, A. and Aoki, R. 1995. Epidemiology of breast
cancer in Japan. Int. J. Epidemiol. 24: 285-291.

13. Bernstein, L. and Ross, R. K. 1993. Endogenous
hormones and breast cancer risk. Epidemiol. Rev. 15:
48-65.
14. Thomas, H. V., Reeves, G. K. and Key, T. J. 1997.
Endogenous estrogen and postmenopausal breast
cancer: a quantitative review. Cancer Causes Control 8:
922-928.
15. Wu, A. H., Pike, M. C. and Stram, D. O. 1999. Metaanalysis: dietary fat intake, serum estrogen levels, and
risk of breast cancer. J. Natl. Cancer Inst. 91: 529-534
16. Prentice, R., Thompson, D., Clifford, C., Gorbach, S.,
Goldin, B. and Byar, D. 1990. Dietary fat reduction and
plasma estradiol concentration in healthy postmenopausal women. J. Natl. Cancer Inst. 82: 129-134.
17. Carter, C. A., Milholland, R. J., Shea, W. and Ip, M. M.
1983. Effect of the prostaglandin tumorigenesis in rats
fed different levels of fat. Cancer Res. 43: 3559-3569.
18. Woutersen, R. A., Appel, M. J., van Garderen-Hoetmer,
A. and Wijnands M. V. 1999. Dietary fat and carcinogenesis. Mutat. Res. 443: 111-127.
19. Kagawa, Y. 1978. Impact of westernization on the
nutrition of Japanese: changes in physique, cancer,
longevity and centenarians. Prev. Med. 7: 205-217.
20. Horrobin, D. F. 1986. The role of essential fatty acids
and prostaglandins in breast cancer. In “Diet, Nutrition and Cancer: A Critical Evaluation, Macronutrients
and Cancer”. pp. 101-124. Reddy, B. S. ed.. CRC Press.
Boca Raton, FL, U.S.A.
21. Abou-El-Ela, S. H., Prasse, K. W., Carroll, R., Wade,
A. E., Dharwadkar, S. and Bunce, O. R. 1988. Eicosanoid synthesis in 7.12-dimethylbenz[a]anthraceneinduced mammary carcinomas in Sprague-Dawley rats
fed primrose oil, menhaden oil or corn oil. Lipid 23:
948-954.
22. Rose, D. P., Connolly, J. M., Rayburn, J. and Coleman,
M. 1995. Influence of diets containing different levels
of eicosapentaenoic or docosahexaenoic acid on the
growth and metastasis of human breast cancer cells in
nude mice. J. Natl. Cancer Inst. 87: 587-592.
23. Fischer, M. A. and Black, H. S. 1991. Modification
of membrane composition, eicosanoid metabolism,
and immunoresponsiveness by dietary omega-3 and
omega-6 fatty acid sources, modulators of ultravioletcarcinogenesis. Photochem. Photobiol. 54: 381-387.

